Goodwill Pharma - Public Comps and Valuation Multiples

Goodwill Pharma Overview

About Goodwill Pharma

Goodwill Pharma Nyrt is a full service pharma partner for the CEE region. The company s core activities include pharmaceutical logistics and distribution, pharmaceutical registration, full pharmaceutical marketing services, medical promotion, manufacturer and brand representation, own-licensed product development, manufacturing and marketing of proprietary pharmaceuticals and dietary supplements.

Founded

HQ

Employees

n/a

Website

goodwillpharma.com

Sectors

Hospitals & Clinics

Financials

Last FY Revenue $0.1M

Last FY EBITDA $10K

EV

$380M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Goodwill Pharma Financials

See Goodwill Pharma valuation multiples based on analyst estimates

Goodwill Pharma P&L

In the most recent fiscal year, Goodwill Pharma reported revenue of $0.1M and EBITDA of $10K.

Goodwill Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Goodwill Pharma valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$0.1M	XXX	XXX	XXX
Gross Profit	XXX	$19K	XXX	XXX	XXX
Gross Margin	XXX	33%	XXX	XXX	XXX
EBITDA	XXX	$10K	XXX	XXX	XXX
EBITDA Margin	XXX	17%	XXX	XXX	XXX
EBIT	XXX	$7K	XXX	XXX	XXX
EBIT Margin	XXX	12%	XXX	XXX	XXX
Net Profit	XXX	$6K	XXX	XXX	XXX
Net Margin	XXX	10%	XXX	XXX	XXX
Net Debt	XXX	$16K	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Goodwill Pharma including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Goodwill Pharma achieved $0.1M in revenue and $10K in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$0.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$19K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	32.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$10K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	16.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$7K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	12.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$6K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	10.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$16K	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Goodwill Pharma

This financial data table provides comprehensive performance metrics for Goodwill Pharma, a company based in Hungary. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Goodwill Pharma reported $0.1M in total revenue.
Fiscal year EBITDA was $10K.
The company maintained a gross profit margin of 32.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 16.7%.
Net profit margin reached 10.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Goodwill Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Goodwill Pharma Stock Performance

Goodwill Pharma has current market cap of HUF 118B (or $360M), and EV of HUF 124B (or $380M).

Market Cap Evolution

Goodwill Pharma Stock Data

As of December 4, 2025, Goodwill Pharma's stock price is HUF 1100 (or $3).

See Goodwill Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$380M	$360M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Goodwill Pharma Valuation Multiples

Goodwill Pharma's trades at 6644.9x EV/Revenue multiple, and 39761.8x EV/EBITDA.

See valuation multiples for Goodwill Pharma and 15K+ public comps

Goodwill Pharma Financial Valuation Multiples

As of December 4, 2025, Goodwill Pharma has market cap of $360M and EV of $380M.

Equity research analysts estimate Goodwill Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Goodwill Pharma's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$360M	XXX	$360M	XXX	XXX	XXX
EV (current)	$380M	XXX	$380M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	6644.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	39761.8x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	55297.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	60346.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-41189.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Goodwill Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Goodwill Pharma Margins & Growth Rates

Goodwill Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Goodwill Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Goodwill Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Goodwill Pharma and other 15K+ public comps

Goodwill Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	17%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	21%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial